Edward Hodgkin
Edward Hodgkin is a Managing Partner of Syncona Investment Management Ltd.
With over 30 years' experience across big pharma, biotech and healthcare investing, Ed has played a central role in the foundation and operational build of Syncona's portfolio companies, founding new businesses and taking executive roles to make them operational.
He was the first CEO and a board member of Autolus Therapeutics (NASDAQ: AUTL), and was the founding CEO of Resolution Therapeutics. He is Chair of Mosaic Therapeutics and Slingshot Therapeutics, and Chair of ALTx, launched through the Slingshot accelerator. He is also a Board member of Resolution Therapeutics and OMass Therapeutics.
Previously, Ed was CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). Ed's early career was spent in research and management positions with Wyeth-Ayerst Inc and British Biotech. He holds a degree and DPhil in Chemistry from the University of Oxford, and was Chairman of the BIA from 2013-2015
Syncona portfolio companies
- OMass Therapeutics (Board member)
- Resolution Therapeutics (Board member)
- Mosaic Therapeutics (Chair)
- Slingshot Therapeutics (Executive Chair)
